Patients withdrawing from study during 21-day stabilization period | FP/SAL 250/50 μg (N = 314) | SAL 50 μg (N = 325) | NominalPValue* |
---|---|---|---|
Any reason | 26 (8%) | 39 (15%) | .105 |
For lack of efficacy or adverse event | 15 (5%) | 24 (7%) | .158 |
For lack of efficacy | 5 (2%) | 13 (4%) | .062 |